ALZ-201 / Alzinova - LARVOL DELTA

Alzinova presents at several conferences and investor meetings in the spring of 2023 (Market Screener) - “Alzinova AB…will present the Company at both Swedish and international investor meetings and conferences during the spring of 2023. In March, the Alzheimer's conference AD/PD™ will take place in Gothenburg, bringing together international industry players and researchers from academia. In June, the Biotech International Convention, (‘US Bio’) will take place, which is an important American business conference for partner meetings. During the event, the Company will present its ALZ-101 vaccine candidate and ALZ-201 antibody to potential partners. During the spring, Alzinova will also present the Company to investors at various capital market events.”

Clinical • Alzheimer's Disease • CNS Disorders

"BioStock: Alzinovas CSO om de nya vetenskapliga rönen kring ALZ-201 https://t.co/tAA8gbTwi2" (@CisionNews)

Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. (PubMed, Alzheimers Res Ther) - "ALZ-201 depletes a toxic species in post-mortem AD brain extracts causing a positive physiological and protective impact on the integrity and morphology of mouse neurons. Its unique specificity indicates that a low-abundant, soluble Aβ42 oligomer may account for much of the neurotoxicity in AD. This critical attribute identifies the potential of ALZ-201 as a novel drug candidate for achieving a true, clinical therapeutic effect in AD."

Journal • Alzheimer's Disease • CNS Disorders

ALZ-201, A MONOCLONAL ANTIBODY THERAPY FOR SPECIFIC NEUTRALISATION OF TOXIC AMYLOID-Β IN ALZHEIMER’S DISEASE. (CTAD 2022) - P1 | "These assemblies are effectively targeted by monoclonal antibodies (mAb) exhibiting selectivity for aggregated forms of Aβ (aducanumab, lecanemab, and gantenerumab) or specificity for pyroglutamated forms (donanemab). Our studies confirm the binding specificity of the unique mAb ALZ-201, which recognises a conformational epitope on the stabilised oligomer antigen in vaccine ALZ-101 and a subset of synthetic Aβ42 oligomers. We previously demonstrated that ALZ-201 specifically binds to a toxic species in post-mortem AD brain extracts to cause a positive physiological and protective impact on the integrity and morphology of mouse neurons. Biosimilars of aducanumab, lecanemab, and gantenerumab, on the other hand, were here shown to exhibit no conformational preference for Aβ, indicating that their weak binding to non-aggregated forms stem almost exclusively from fast binding off-rates."

Alzheimer's Disease • CNS Disorders

"BioStock: Alzinova avancerar med ALZ-201 https://t.co/h6zUMi6yT1" (@CisionNews)

Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer's clinical trials (PRNewswire) - "Alzinova AB...announces the initiation of the next step in the preclinical development of its oligomer-specific monoclonal antibody, ALZ-201. The Company is developing ALZ-201 as a second product in its portfolio of Alzheimer's treatments, along with its vaccine candidate, ALZ-101, which is currently in Phase 1b clinical development....Alzinova has selected a collaboration partner to manage this work as a step in preparing the antibody for clinical trials."

Preclinical • Alzheimer's Disease • CNS Disorders

"The Board of Directors resolves on a rights issue of units of approximately SEK 42.5 million, part of the issue proceeds is intended to finance further development of ALZ-201 https://t.co/OKFV5rtmA2" (@CisionNews)

"Prekliniska data bekräftar den unika specificiteten och sjukdomsmodifierande potentialen hos Alzinovas monoklonala antikropp, ALZ-201 https://t.co/BXQsEddvzP" (@CisionNews)

[VIRTUAL] A novel specific Aβ 42 oligomer antibody ameliorates the neurotoxicity of patient-derived brain extracts (AAIC 2021) - "The results demonstrate that very small amounts of soluble aggregated Aβ 42 likely account for a large part of the toxicity in AD patients. The unique antibody, ALZ-201, is capable of depleting these without targeting other forms of Aβ. Since this natural toxic form of Aβ is extremely low in abundance, this feature may be a critical attribute for achieving a true therapeutic effect in actual patients."

Clinical • Alzheimer's Disease • CNS Disorders

"ALZ-201 antibody has demonstrated selectivity and therapeutic effect in postmortem human brain tissue from AD patients #AAIC21" (@Cortellis)

Clinical

Alzinova presents preclinical data on Alzheimer disease candidates at the AAIC conference (PRNewswire) - “Alzinova…today presenting data on the monoclonal antibody, ALZ-201, at the Alzheimer's Association International Conference (AAIC) held in Denver, USA and online. The preclinical data support the continued development of Alzinova's lead candidate, ALZ-101, which is further in development and is expected to enter the clinical phase with a Phase 1b study in Alzheimer's patients during the third quarter of 2021…These data indicate that it has very high selectivity for the toxic form of the Aβ peptide and a binding profile that differs from other known antibodies in the field. The selectivity may be a critical attribute for achieving a true specific therapeutic effect with favorable tolerability in patients with Alzheimer's disease.”

New P1 trial • Preclinical • Alzheimer's Disease • CNS Disorders